动物造模,药效评价,自发白血病 z-bio 2024-07-08 463

　　AKR spontaneous leukemia mice are born with oncogenic RNA viruses, and their therapeutic response to drugs is similar to that of childhood acute lymphoblastic leukemia.

　　[Model characteristics] AKR mice are a high incidence strain of leukemia. The incidence of lymphocytic leukemia is 76%~90% in males and 68%~90% in females. AKR mice aged 6-12 months showed splenomegaly and lymph node enlargement, with abnormal blood count. The course of leukemia varies among different mice. The next day after being diagnosed with leukemia through blood tests, they can be paired and grouped, and the test drug can be administered to observe the results. Observation indicators include peripheral blood count, white blood cell count, lymph node and spleen size, and animal survival time. The survival time of the effective group was longer than that of the control group, and the induction and maintenance of remission of the drug were evaluated based on blood count.

　　【 Model Evaluation and Application 】 The spontaneous tumors in AKR mouse leukemia models are usually more similar to those induced by experimental methods compared to those in humans, which is beneficial for extrapolating animal experimental results to humans; Moreover, the conditions for tumor occurrence are relatively natural, and it is possible to discover environmental or other carcinogenic factors that were not previously discovered through careful observation and statistical analysis. The role of genetic factors in tumor occurrence can be emphasized. The etiology of spontaneous tumors in animals is often determined by their genetic characteristics, which is far from the etiology of tumors in humans. The growth rate of tumors varies greatly among different animals, making it difficult to obtain a large number of uniformly growing tumor bearing animals within a limited time, resulting in defects such as longer observation time and higher experimental costs. Therefore, spontaneous tumor animal models are rarely widely used in routine screening of anti-tumor drugs.